Bio‑Path outlines a robust development and regulatory path ahead, aiming to advance both cancer and obesity-focused therapies using …
Bio‑Path outlines a robust development and regulatory path ahead, aiming to advance both cancer and obesity-focused therapies using …
A landmark U.S. FDA nod for Datopotamab deruxtecan (Datroway) marks a promising advance for treating metastatic HR‑positive, HER2‑negative …
Neumora Therapeutics sees its share value collapse as its lead antidepressant candidate, navacaprant, fails to outperform placebo in …
Caption By the end of 2024, emerging studies point to GLP‑1 receptor agonists—once mainly weight‑loss drugs—finding versatile application …
Humacyte’s Symvess offers a novel solution for patients with severe vascular injuries, marking a significant advancement in trauma …
A landmark regulatory update aims to speed approvals, reduce bureaucracy, and strengthen the UK’s position as a global …
December marks a turning point in computational biology, with Exscientia’s AI-designed oncology candidate advancing to mid-stage trials—reshaping how …
Roche’s PD-L1 inhibitor demonstrates durable response in RET-mutant thyroid cancer, offering a new option for patients with limited …
Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
GSK’s long-acting biologic reduces exacerbations and improves lung function in eosinophilic asthma, offering a potential once-yearly treatment option.
Already a subscriber? Log in